신장암 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)
Kidney Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1530950
리서치사:Transparency Market Research
발행일:2024년 06월
페이지 정보:영문 189 Pages
라이선스 & 가격 (부가세 별도)
한글목차
신장암 진단 시장 - 조사 범위
TMR의 조사 보고서인 "신장암 진단 세계 시장"은 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2024년을 기준 연도로, 2034년을 예측연도로 하여 2018년부터 2034년까지의 세계 신장암 진단 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 신장암 진단 시장의 연평균 성장률(CAGR %)도 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서 분석가들은 주요 오피니언 리더, 업계 리더 및 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 신장암 진단 시장을 추론했습니다.
시장 스냅샷
2023년 시장 규모
36억 달러
2034년 시장 규모
69억 달러
CAGR
6.2%
이 보고서는 세계 신장암 진단 시장의 경쟁 환경을 조사하고 있습니다. 세계 신장암 진단 시장에서 사업을 전개하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성별로 프로파일링되어 있습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등은 이 보고서에서 소개하는 세계 신장암 진단 시장 기업의 속성입니다.
목차
제1장 서문
제2장 가정과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
소개
개요
시장 역학
세계의 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19에 의한 산업에 대한 영향
제6장 세계의 시장 분석과 예측 : 제품 유형별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 제품 유형별, 2020-2034년
플랫폼 기반 제품
계측 기기 기반 제품
키트와 시약
기타(소모품 등)
시장 매력 : 제품 유형별
제7장 세계의 시장 분석과 예측 : 검사 유형별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 검사 유형별, 2020-2034년
생검
영상 검사
혈액 검사
기타(유전자 검사 등)
시장 매력 : 검사 유형별
제8장 세계의 시장 분석과 예측 : 암 스테이지별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 암 스테이지별, 2020-2034년
스테이지 1
스테이지 2
스테이지 3
스테이지 4
시장 매력 : 암스테이지별
제9장 세계의 시장 분석과 예측 : 종양 유형별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 종양 유형별, 2020-2034년
신세포암
명세포암
비명세포암
시장 매력 : 종양 유형별
제10장 세계의 시장 분석과 예측 : 기술별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 기술별, 2020-2034년
FISH(Fluorescent In Situ Hybridization)
차세대 시퀀싱
형광면역측정법
CGH(Comparative Genomic Hybridization)
기타(면역조직화학 등)
시장 매력 : 기술별
제11장 세계의 시장 분석과 예측 : 최종사용자별
소개와 정의
주요 조사 결과·발전
시장 금액 예측 : 최종사용자별, 2020-2034년
병원
암 연구 센터
종양과 클리닉
진단 센터
외래 수술 센터
기타(조사기관 등)
시장 매력 : 최종사용자별
제12장 세계의 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별, 2020-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장 매력 : 지역별
제13장 북미의 시장 분석과 예측
제14장 유럽의 시장 분석과 예측
제15장 아시아태평양의 시장 분석과 예측
제16장 라틴아메리카의 시장 분석과 예측
제17장 중동 및 아프리카의 시장 분석과 예측
제18장 경쟁 상황
시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
시장 점유율 분석 : 기업별(2023)
기업 개요
Siemens Healthineers
Koninklijke Philips N.V.
FUJIFILM Holdings Corporation
Grail
Laboratory Corporation of America Holdings
Thermo Fisher Scientific
Myriad Genetics, Inc.
Canon Medical Systems Corporation
QIAGEN N.V.
Illumina, Inc.
Ambry Genetics
Invitae Corp.
Centogene N.V.
ksm
영문 목차
영문목차
Kidney Cancer Diagnostics Market - Scope of Report
TMR's report on the global kidney cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kidney cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kidney cancer diagnostics market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the kidney cancer diagnostics market.
Market Snapshot
Market Value in 2023
US$ 3.6 Bn
Market Value in 2034
US$ 6.9 Bn
CAGR
6.2%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kidney cancer diagnostics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kidney cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kidney cancer diagnostics market.
The report delves into the competitive landscape of the global kidney cancer diagnostics market. Key players operating in the global kidney cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kidney cancer diagnostics market profiled in this report.
Key Questions Answered in Global kidney cancer diagnostics Market Report:
What is the sales/revenue generated by kidney cancer diagnostics across all regions during the forecast period?
What are the opportunities in the global kidney cancer diagnostics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Kidney Cancer Diagnostics Market - Research Objectives and Research Approach
The comprehensive report on the global kidney cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global kidney cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kidney cancer diagnostics market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Kidney Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Kidney Cancer Diagnostics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2020-2034
6.3.1. Platform-based Products
6.3.2. Instrument-based Products
6.3.3. Kits and Reagents
6.3.4. Others (Consumables, etc.)
6.4. Market Attractiveness, by Product Type
7. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Test Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Test Type, 2020-2034
7.3.1. Biopsy
7.3.2. Imaging Tests
7.3.3. Blood Tests
7.3.4. Others (Genetic Testing, etc.)
7.4. Market Attractiveness, by Test Type
8. Global Kidney Cancer Diagnostics Market Analysis and Forecast, By Cancer Stage
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Cancer Stage, 2020-2034
8.3.1. Stage 1
8.3.2. Stage 2
8.3.3. Stage 3
8.3.4. Stage 4
8.4. Market Attractiveness, By Cancer Stage
9. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Tumor Type
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Tumor Type, 2020-2034
9.3.1. Renal Cell Carcinoma
9.3.2. Clear Cell Carcinoma
9.3.3. Non-clear Cell Carcinoma
9.4. Market Attractiveness, by Tumor Type
10. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Technology
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Tumor Type, 2020-2034
10.3.1. Fluorescent In Situ Hybridization
10.3.2. Next Generation Sequencing
10.3.3. Fluoroimmunoassay
10.3.4. Comparative Genomic Hybridization
10.3.5. Others (Immunohistochemical, etc.)
10.4. Market Attractiveness, by Tumor Type
11. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by End-user
11.1. Introduction and Definitions
11.2. Key Findings/Developments
11.3. Market Value Forecast, by End-user, 2020-2034
11.3.1. Hospitals
11.3.2. Cancer Research Centers
11.3.3. Oncology Clinics
11.3.4. Diagnostic Centers
11.3.5. Ambulatory Surgery Centers
11.3.6. Others (Research Institutes, etc.)
11.4. Market Attractiveness, by End-user
12. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region, 2020-2034
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness, by Region
13. North America Kidney Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2020-2034
13.2.1. Platform-based Products
13.2.2. Instrument-based Products
13.2.3. Kits and Reagents
13.2.4. Others (Consumables, etc.)
13.3. Market Attractiveness, by Product Type
13.4. Market Value Forecast, by Test Type, 2020-2034
13.4.1. Biopsy
13.4.2. Imaging Tests
13.4.3. Blood Tests
13.4.4. Others (Genetic Testing, etc.)
13.5. Market Attractiveness, by Test Type
13.6. Market Value Forecast, By Cancer Stage, 2020-2034
13.6.1. Stage 1
13.6.2. Stage 2
13.6.3. Stage 3
13.6.4. Stage 4
13.7. Market Attractiveness, By Cancer Stage
13.8. Market Value Forecast, by Tumor Type, 2020-2034
13.8.1. Renal Cell Carcinoma
13.8.2. Clear Cell Carcinoma
13.8.3. Non-clear Cell Carcinoma
13.9. Market Attractiveness, by Tumor Type
13.10. Market Value Forecast, by Technology 2020-2034
13.10.1. Fluorescent In Situ Hybridization
13.10.2. Next Generation Sequencing
13.10.3. Fluoroimmunoassay
13.10.4. Comparative Genomic Hybridization
13.10.5. Others (Immunohistochemical, etc.)
13.11. Market Attractiveness, by Technology
13.12. Market Value Forecast, by End-user, 2020-2034
13.12.1. Hospitals
13.12.2. Cancer Research Centers
13.12.3. Oncology Clinics
13.12.4. Diagnostic Centers
13.12.5. Ambulatory Surgery Centers
13.12.6. Others (Research Institutes, etc.)
13.13. Market Attractiveness, by End-user
13.14. Market Value Forecast, by Country/Sub-region, 2020-2034
13.14.1. U.S.
13.14.2. Canada
13.15. Market Attractiveness Analysis
13.15.1. By Product Type
13.15.2. By Test Type
13.15.3. By Cancer Stage
13.15.4. By Tumor Type
13.15.5. By End-user
13.15.6. By Country
14. Europe Kidney Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2020-2034
14.2.1. Platform-based Products
14.2.2. Instrument-based Products
14.2.3. Kits and Reagents
14.2.4. Others (Consumables, etc.)
14.3. Market Attractiveness, by Product Type
14.4. Market Value Forecast, by Test Type, 2020-2034
14.4.1. Biopsy
14.4.2. Imaging Tests
14.4.3. Blood Tests
14.4.4. Others (Genetic Testing, etc.)
14.5. Market Attractiveness, by Test Type
14.6. Market Value Forecast, By Cancer Stage, 2020-2034
14.6.1. Stage 1
14.6.2. Stage 2
14.6.3. Stage 3
14.6.4. Stage 4
14.7. Market Attractiveness, By Cancer Stage
14.8. Market Value Forecast, by Tumor Type, 2020-2034
14.8.1. Renal Cell Carcinoma
14.8.2. Clear Cell Carcinoma
14.8.3. Non-clear Cell Carcinoma
14.9. Market Attractiveness, by Tumor Type
14.10. Market Value Forecast, by Technology, 2020-2034
14.10.1. Fluorescent In Situ Hybridization
14.10.2. Next Generation Sequencing
14.10.3. Fluoroimmunoassay
14.10.4. Comparative Genomic Hybridization
14.10.5. Others (Immunohistochemical, etc.)
14.11. Market Attractiveness, by Technology
14.12. Market Value Forecast, by End-user, 2020-2034
14.12.1. Hospitals
14.12.2. Cancer Research Centers
14.12.3. Oncology Clinics
14.12.4. Diagnostic Centers
14.12.5. Ambulatory Surgery Centers
14.12.6. Others (Research Institutes, etc.)
14.13. Market Attractiveness, by End-user
14.14. Market Value Forecast, by Country/Sub-region, 2020-2034
14.14.1. Germany
14.14.2. U.K.
14.14.3. France
14.14.4. Italy
14.14.5. Spain
14.14.6. Rest of Europe
14.15. Market Attractiveness Analysis
14.15.1. By Product Type
14.15.2. By Test Type
14.15.3. By Cancer Stage
14.15.4. By Tumor Type
14.15.5. By End-user
14.15.6. By Country/Sub-region
15. Asia Pacific Kidney Cancer Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2020-2034
15.2.1. Platform-based Products
15.2.2. Instrument-based Products
15.2.3. Kits and Reagents
15.2.4. Others (Consumables, etc.)
15.3. Market Attractiveness, by Product Type
15.4. Market Value Forecast, by Test Type, 2020-2034
15.4.1. Biopsy
15.4.2. Imaging Tests
15.4.3. Blood Tests
15.4.4. Others (Genetic Testing, etc.)
15.5. Market Attractiveness, by Test Type
15.6. Market Value Forecast, By Cancer Stage, 2020-2034
15.6.1. Stage 1
15.6.2. Stage 2
15.6.3. Stage 3
15.6.4. Stage 4
15.7. Market Attractiveness, By Cancer Stage
15.8. Market Value Forecast, by Tumor Type, 2020-2034
15.8.1. Renal Cell Carcinoma
15.8.2. Clear Cell Carcinoma
15.8.3. Non-clear Cell Carcinoma
15.9. Market Attractiveness, by Tumor Type
15.10. Market Value Forecast, by Technology 2020-2034
15.10.1. Fluorescent In Situ Hybridization
15.10.2. Next Generation Sequencing
15.10.3. Fluoroimmunoassay
15.10.4. Comparative Genomic Hybridization
15.10.5. Others (Immunohistochemical, etc.)
15.11. Market Attractiveness, by Technology
15.12. Market Value Forecast, by End-user, 2020-2034
15.12.1. Hospitals
15.12.2. Cancer Research Centers
15.12.3. Oncology Clinics
15.12.4. Diagnostic Centers
15.12.5. Ambulatory Surgery Centers
15.12.6. Others (Research Institutes, etc.)
15.13. Market Attractiveness, by End-user
15.14. Market Value Forecast, by Country/Sub-region, 2020-2034
15.14.1. China
15.14.2. Japan
15.14.3. India
15.14.4. Australia & New Zealand
15.14.5. Rest of Asia Pacific
15.15. Market Attractiveness Analysis
15.15.1. By Product Type
15.15.2. By Test Type
15.15.3. By Cancer Stage
15.15.4. By Tumor Type
15.15.5. By End-user
15.15.6. By Country/Sub-region
16. Latin America Kidney Cancer Diagnostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product Type, 2020-2034
16.2.1. Platform-based Products
16.2.2. Instrument-based Products
16.2.3. Kits and Reagents
16.2.4. Others (Consumables, etc.)
16.3. Market Attractiveness, by Product Type
16.4. Market Value Forecast, by Test Type, 2020-2034
16.4.1. Biopsy
16.4.2. Imaging Tests
16.4.3. Blood Tests
16.4.4. Others (Genetic Testing, etc.)
16.5. Market Attractiveness, by Test Type
16.6. Market Value Forecast, By Cancer Stage, 2020-2034
16.6.1. Stage 1
16.6.2. Stage 2
16.6.3. Stage 3
16.6.4. Stage 4
16.7. Market Attractiveness, By Cancer Stage
16.8. Market Value Forecast, by Tumor Type, 2020-2034
16.8.1. Renal Cell Carcinoma
16.8.2. Clear Cell Carcinoma
16.8.3. Non-clear Cell Carcinoma
16.9. Market Attractiveness, by Tumor Type
16.10. Market Value Forecast, by Technology, 2020-2034
16.10.1. Fluorescent In Situ Hybridization
16.10.2. Next Generation Sequencing
16.10.3. Fluoroimmunoassay
16.10.4. Comparative Genomic Hybridization
16.10.5. Others (Immunohistochemical, etc.)
16.11. Market Attractiveness, by Technology
16.12. Market Value Forecast, by End-user, 2020-2034
16.12.1. Hospitals
16.12.2. Cancer Research Centers
16.12.3. Oncology Clinics
16.12.4. Diagnostic Centers
16.12.5. Ambulatory Surgery Centers
16.12.6. Others (Research Institutes, etc.)
16.13. Market Attractiveness, by End-user
16.14. Market Value Forecast, by Country/Sub-region, 2020-2034
16.14.1. Brazil
16.14.2. Mexico
16.14.3. Rest of Latin America
16.15. Market Attractiveness Analysis
16.15.1. By Product Type
16.15.2. By Test Type
16.15.3. By Cancer Stage
16.15.4. By Tumor Type
16.15.5. By End-user
16.15.6. By Country/Sub-region
17. Middle East & Africa Kidney Cancer Diagnostics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Product Type, 2020-2034
17.2.1. Platform-based Products
17.2.2. Instrument-based Products
17.2.3. Kits and Reagents
17.2.4. Others (Consumables, etc.)
17.3. Market Attractiveness, by Product Type
17.4. Market Value Forecast, by Test Type, 2020-2034
17.4.1. Biopsy
17.4.2. Imaging Tests
17.4.3. Blood Tests
17.4.4. Others (Genetic Testing, etc.)
17.5. Market Attractiveness, by Test Type
17.6. Market Value Forecast, By Cancer Stage, 2020-2034
17.6.1. Stage 1
17.6.2. Stage 2
17.6.3. Stage 3
17.6.4. Stage 4
17.7. Market Attractiveness, By Cancer Stage
17.8. Market Value Forecast, by Tumor Type, 2020-2034
17.8.1. Renal Cell Carcinoma
17.8.2. Clear Cell Carcinoma
17.8.3. Non-clear Cell Carcinoma
17.9. Market Attractiveness, by Tumor Type
17.10. Market Value Forecast, by Technology, 2020-2034
17.10.1. Fluorescent In Situ Hybridization
17.10.2. Next Generation Sequencing
17.10.3. Fluoroimmunoassay
17.10.4. Comparative Genomic Hybridization
17.10.5. Others (Immunohistochemical, etc.)
17.11. Market Attractiveness, by Technology
17.12. Market Value Forecast, by End-user, 2020-2034
17.12.1. Hospitals
17.12.2. Ambulatory Surgical Centers
17.12.3. Nursing Centers
17.12.4. Others (Long Term Care Centers, etc.)
17.13. Market Attractiveness, by End-user
17.14. Market Value Forecast, by Country/Sub-region, 2020-2034
17.14.1. GCC Countries
17.14.2. South Africa
17.14.3. Rest of Middle East & Africa
17.15. Market Attractiveness Analysis
17.15.1. By Product Type
17.15.2. By Test Type
17.15.3. By Cancer Stage
17.15.4. By Tumor Type
17.15.5. By End-user
17.15.6. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competition Matrix (By Tier and Size of Companies)
18.2. Market Share Analysis, by Company (2023)
18.3. Company Profiles
18.3.1. Siemens Healthineers
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Koninklijke Philips N.V.
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. FUJIFILM Holdings Corporation
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. Grail
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. Laboratory Corporation of America Holdings
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.6. Thermo Fisher Scientific
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Myriad Genetics, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Canon Medical Systems Corporation
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
18.3.9. QIAGEN N.V.
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Illumina, Inc.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. Financial Overview
18.3.10.4. SWOT Analysis
18.3.10.5. Strategic Overview
18.3.11. Ambry Genetics
18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.11.2. Product Portfolio
18.3.11.3. Financial Overview
18.3.11.4. SWOT Analysis
18.3.11.5. Strategic Overview
18.3.12. Invitae Corp.
18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.12.2. Product Portfolio
18.3.12.3. Financial Overview
18.3.12.4. SWOT Analysis
18.3.12.5. Strategic Overview
18.3.13. Centogene N.V.
18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
